Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

作者: Sei Hoon Yang , Leah E Mechanic , Ping Yang , Maria Teresa Landi , Elise D Bowman

DOI: 10.1158/1078-0432.CCR-04-1853

关键词:

摘要: We evaluated somatic genetic alterations in the kinase domain of EGFR gene tumors 219 non-small cell lung cancer patients primarily Caucasian and African American origins. identified 26 (12%) whose had a mutation gene, 11 (5%) carried novel genomic variations consistent with germ-line polymorphisms. All but one were affected adenocarcinoma. mutations more frequent women nonsmokers, significant portion men (12 26) current or past smokers accounted for half (13 26). Screening subjects may identify could respond to targeted therapy using tyrosine inhibitors.

参考文章(16)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Masakazu Ueda, Nobuyoshi Shimizu, Nobuyoshi Shimizu, Osahiko Abe, John Hunts, Soji Ozawa, Ira Pastan, HYPERPRODUCTION AND GENE AMPLIFICATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN SQUAMOUS CELL CARCINOMAS Japanese Journal of Cancer Research. ,vol. 76, pp. 663- 666 ,(1985) , 10.20772/CANCERSCI1985.76.8_663
Pasi A. Jänne, Sarada Gurubhagavatula, Beow Y. Yeap, Joan Lucca, Patricia Ostler, Arthur T. Skarin, Panos Fidias, Thomas J. Lynch, Bruce E. Johnson, Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study Lung Cancer. ,vol. 44, pp. 221- 230 ,(2004) , 10.1016/J.LUNGCAN.2003.12.014
Fortunato Ciardiello, Ferdinando De Vita, Michele Orditura, Giampaolo Tortora, The role of EGFR inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology. ,vol. 16, pp. 130- 135 ,(2004) , 10.1097/00001622-200403000-00008
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Antonio L Visbal, Brent A Williams, Francis C Nichols, Randolph S Marks, James R Jett, Marie-Christine Aubry, Eric S Edell, Jason A Wampfler, Julian R Molina, Ping Yang, Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. The Annals of Thoracic Surgery. ,vol. 78, pp. 209- 215 ,(2004) , 10.1016/J.ATHORACSUR.2003.11.021
Fred R. Hirsch, Giorgio V. Scagliotti, Corey J. Langer, Marileila Varella-Garcia, Wilbur A. Franklin, Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. ,vol. 41, pp. 29- 42 ,(2003) , 10.1016/S0169-5002(03)00137-5
Mark G. Kris, Ronald B. Natale, Roy S. Herbst, Thomas J. Lynch, Jr, Diane Prager, Chandra P. Belani, Joan H. Schiller, Karen Kelly, Harris Spiridonidis, Alan Sandler, Kathy S. Albain, David Cella, Michael K. Wolf, Steven D. Averbuch, Judith J. Ochs, Andrea C. Kay, Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial JAMA. ,vol. 290, pp. 2149- 2158 ,(2003) , 10.1001/JAMA.290.16.2149
S. M. Dong, G. Traverso, C. Johnson, L. Geng, R. Favis, K. Boynton, K. Hibi, S. N. Goodman, M. D'Allessio, P. Paty, S. R. Hamilton, D. Sidransky, F. Barany, B. Levin, A. Shuber, K. W. Kinzler, B. Vogelstein, J. Jen, Detecting Colorectal Cancer in Stool With the Use of Multiple Genetic Targets Journal of the National Cancer Institute. ,vol. 93, pp. 858- 865 ,(2001) , 10.1093/JNCI/93.11.858
D Maxwell Parkin, Global cancer statistics in the year 2000 The Lancet Oncology. ,vol. 2, pp. 533- 543 ,(2001) , 10.1016/S1470-2045(01)00486-7